Also, some investigations demonstrated that PCA3 levels in the urine may be significantly affected by androgen deprivation therapy, which would restrict the consideration of PCA3 levels to monitor PCa clinical course [83, 84]. The gene discussed is PCA3; the disease is posterior cortical atrophy.